Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)
Other Treatments Global Adoption
Outcomes in COVID-19 aspirin studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Exclusions   Mortality   Ventilation   ICU   Serious outcomes   Recovery   Cases   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 20% 23 80,752 Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 23% 21 77,074 Mortality 17% 20 70,208 Ventilation 8% 7 47,174 ICU admission -34% 3 706 Recovery 6% 1 14,892 Cases 44% 3 10,749 Viral clearance 9% 2 710 RCTs 4% 2 29,784 Peer-reviewed 18% 20 65,511 Prophylaxis 15% 11 46,056 Late 23% 12 34,696 Aspirin for COVID-19 c19aspirin.com Dec 3, 2021 Favors aspirin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alamdari -28% 1.28 [0.67-2.43] death 9/53 54/406 Improvement, RR [CI] Treatment Control Meizlish (PSM) 48% 0.52 [0.34-0.81] death 319 (n) 319 (n) Liu (PSM) 75% 0.25 [0.07-0.87] death 2/28 11/204 Mura 15% 0.85 [0.69-1.01] death 527 (n) 527 (n) Chow 47% 0.53 [0.31-0.90] death 26/98 73/314 Sahai (PSM) 13% 0.87 [0.56-1.34] death 33/248 38/248 Horby (RCT) 4% 0.96 [0.89-1.04] death 1,222/7,351 1,299/7,541 Abdelwahab -8% 1.08 [0.15-3.82] ventilation 11/31 6/36 Al Harthi (PSM) 27% 0.73 [0.56-0.97] death 98/176 107/173 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Zhao 43% 0.57 [0.41-0.78] death 121/473 140/473 RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) Tau​2​ = 0.03; I​2​ = 77.1% Late treatment 23% 0.77 [0.67-0.89] 1,536/16,779 1,751/17,917 23% improvement Huh 71% 0.29 [0.14-0.58] cases population-based cohort Improvement, RR [CI] Treatment Control Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Yuan 4% 0.96 [0.47-1.72] death 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] death 272/6,300 661/6,300 Merzon 28% 0.72 [0.53-0.99] cases 73/1,621 589/8,856 Mulhem -14% 1.14 [0.93-1.40] death 300/1,354 216/1,865 Chow (PSM) 19% 0.81 [0.76-0.87] death 1,280/6,781 2,271/10,566 Kim (PSM) -700% 8.00 [1.07-59.6] death 6/15 1/20 Basheer -13% 1.13 [1.05-1.21] death 45/140 29/250 Sisinni -7% 1.07 [0.89-1.29] death 93/253 251/731 Pérez-Segura -49% 1.49 [1.20-1.80] death 66/155 183/608 Tau​2​ = 0.16; I​2​ = 94.1% Prophylaxis 15% 0.85 [0.64-1.12] 2,147/16,680 4,243/29,376 15% improvement All studies 20% 0.80 [0.70-0.92] 3,683/33,459 5,994/47,293 20% improvement 23 aspirin COVID-19 studies c19aspirin.com Dec 3, 2021 Tau​2​ = 0.07; I​2​ = 90.3%; Z = 3.11 Effect extraction pre-specified Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Meizlish (PSM) 48% 0.52 [0.34-0.81] death 319 (n) 319 (n) Improvement, RR [CI] Treatment Control Liu (PSM) 75% 0.25 [0.07-0.87] death 2/28 11/204 Mura 15% 0.85 [0.69-1.01] death 527 (n) 527 (n) Chow 47% 0.53 [0.31-0.90] death 26/98 73/314 Sahai (PSM) 13% 0.87 [0.56-1.34] death 33/248 38/248 Horby (RCT) 4% 0.96 [0.89-1.04] death 1,222/7,351 1,299/7,541 Abdelwahab -8% 1.08 [0.15-3.82] ventilation 11/31 6/36 Al Harthi (PSM) 27% 0.73 [0.56-0.97] death 98/176 107/173 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Zhao 43% 0.57 [0.41-0.78] death 121/473 140/473 RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) Tau​2​ = 0.03; I​2​ = 78.7% Late treatment 24% 0.76 [0.66-0.88] 1,527/16,726 1,697/17,511 24% improvement Huh 71% 0.29 [0.14-0.58] cases population-based cohort Improvement, RR [CI] Treatment Control Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Yuan 4% 0.96 [0.47-1.72] death 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] death 272/6,300 661/6,300 Merzon 28% 0.72 [0.53-0.99] cases 73/1,621 589/8,856 Chow (PSM) 19% 0.81 [0.76-0.87] death 1,280/6,781 2,271/10,566 Kim (PSM) -700% 8.00 [1.07-59.6] death 6/15 1/20 Basheer -13% 1.13 [1.05-1.21] death 45/140 29/250 Sisinni -7% 1.07 [0.89-1.29] death 93/253 251/731 Pérez-Segura -49% 1.49 [1.20-1.80] death 66/155 183/608 Tau​2​ = 0.18; I​2​ = 94.0% Prophylaxis 18% 0.82 [0.60-1.11] 1,847/15,326 4,027/27,511 18% improvement All studies 23% 0.77 [0.67-0.89] 3,374/32,052 5,724/45,022 23% improvement 21 aspirin COVID-19 studies after exclusions c19aspirin.com Dec 3, 2021 Tau​2​ = 0.07; I​2​ = 90.6%; Z = 3.48 Effect extraction pre-specified Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alamdari -28% 1.28 [0.67-2.43] 9/53 54/406 Improvement, RR [CI] Treatment Control Meizlish (PSM) 48% 0.52 [0.34-0.81] 319 (n) 319 (n) Liu (PSM) 75% 0.25 [0.07-0.87] 2/28 11/204 Mura 15% 0.85 [0.69-1.01] 527 (n) 527 (n) Chow 47% 0.53 [0.31-0.90] 26/98 73/314 Sahai (PSM) 13% 0.87 [0.56-1.34] 33/248 38/248 Horby (RCT) 4% 0.96 [0.89-1.04] 1,222/7,351 1,299/7,541 Al Harthi (PSM) 27% 0.73 [0.56-0.97] 98/176 107/173 Kim (PSM) 34% 0.66 [0.36-1.23] 14/124 23/135 Zhao 43% 0.57 [0.41-0.78] 121/473 140/473 RECOVERY (RCT) 4% 0.96 [0.89-1.04] 7,351 (n) 7,541 (n) Tau​2​ = 0.03; I​2​ = 79.1% Late treatment 23% 0.77 [0.66-0.88] 1,525/16,748 1,745/17,881 23% improvement Wang 58% 0.42 [0.01-1.98] 1/9 13/49 Improvement, RR [CI] Treatment Control Yuan 4% 0.96 [0.47-1.72] 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] 272/6,300 661/6,300 Mulhem -14% 1.14 [0.93-1.40] 300/1,354 216/1,865 Chow (PSM) 19% 0.81 [0.76-0.87] 1,280/6,781 2,271/10,566 Kim (PSM) -700% 8.00 [1.07-59.6] 6/15 1/20 Basheer -13% 1.13 [1.05-1.21] 45/140 29/250 Sisinni -7% 1.07 [0.89-1.29] 93/253 251/731 Pérez-Segura -49% 1.49 [1.20-1.80] 66/155 183/608 Tau​2​ = 0.17; I​2​ = 95.0% Prophylaxis 4% 0.96 [0.70-1.31] 2,074/15,059 3,654/20,520 4% improvement All studies 17% 0.83 [0.71-0.96] 3,599/31,807 5,399/38,401 17% improvement 20 aspirin COVID-19 mortality results c19aspirin.com Dec 3, 2021 Tau​2​ = 0.07; I​2​ = 91.2%; Z = 2.57 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chow 44% 0.56 [0.37-0.85] 35/98 152/314 Improvement, RR [CI] Treatment Control Horby (RCT) 5% 0.95 [0.87-1.05] 772/6,993 829/7,169 Abdelwahab -8% 1.08 [0.15-3.82] 11/31 6/36 Kim (PSM) -102% 2.02 [0.83-4.90] 13/124 7/135 RECOVERY (RCT) 5% 0.95 [0.87-1.05] 7,351 (n) 7,541 (n) Tau​2​ = 0.02; I​2​ = 73.8% Late treatment 12% 0.88 [0.73-1.07] 831/14,597 994/15,195 12% improvement Chow (PSM) 3% 0.97 [0.93-1.02] 2,122/6,781 3,403/10,566 Improvement, RR [CI] Treatment Control Kim (PSM) -433% 5.33 [0.66-43.0] 4/15 1/20 Tau​2​ = 0.88; I​2​ = 60.9% Prophylaxis -63% 1.63 [0.35-7.58] 2,126/6,796 3,404/10,586 -63% improvement All studies 8% 0.92 [0.83-1.03] 2,957/21,393 4,398/25,781 8% improvement 7 aspirin COVID-19 mechanical ventilation results c19aspirin.com Dec 3, 2021 Tau​2​ = 0.01; I​2​ = 68.6%; Z = 1.41 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chow 43% 0.57 [0.38-0.85] 38/98 160/314 Improvement, RR [CI] Treatment Control Kim (PSM) -91% 1.91 [0.57-6.35] 7/124 4/135 Tau​2​ = 0.53; I​2​ = 72.8% Late treatment 10% 0.90 [0.29-2.83] 45/222 164/449 10% improvement Kim (PSM) -433% 5.33 [0.66-43.0] 4/15 1/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00; I​2​ = 0.0% Prophylaxis -433% 5.33 [0.66-43.0] 4/15 1/20 -433% improvement All studies -34% 1.34 [0.38-4.72] 49/237 165/469 -34% improvement 3 aspirin COVID-19 ICU results c19aspirin.com Dec 3, 2021 Tau​2​ = 0.86; I​2​ = 74.3%; Z = 0.46 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alamdari -28% 1.28 [0.67-2.43] death 9/53 54/406 Improvement, RR [CI] Treatment Control Meizlish (PSM) 48% 0.52 [0.34-0.81] death 319 (n) 319 (n) Liu (PSM) 75% 0.25 [0.07-0.87] death 2/28 11/204 Mura 15% 0.85 [0.69-1.01] death 527 (n) 527 (n) Chow 47% 0.53 [0.31-0.90] death 26/98 73/314 Sahai (PSM) 13% 0.87 [0.56-1.34] death 33/248 38/248 Horby (RCT) 4% 0.96 [0.89-1.04] death 1,222/7,351 1,299/7,541 Abdelwahab -8% 1.08 [0.15-3.82] ventilation 11/31 6/36 Al Harthi (PSM) 27% 0.73 [0.56-0.97] death 98/176 107/173 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Zhao 43% 0.57 [0.41-0.78] death 121/473 140/473 RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) Tau​2​ = 0.03; I​2​ = 77.1% Late treatment 23% 0.77 [0.67-0.89] 1,536/16,779 1,751/17,917 23% improvement Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Improvement, RR [CI] Treatment Control Yuan 4% 0.96 [0.47-1.72] death 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] death 272/6,300 661/6,300 Mulhem -14% 1.14 [0.93-1.40] death 300/1,354 216/1,865 Chow (PSM) 19% 0.81 [0.76-0.87] death 1,280/6,781 2,271/10,566 Kim (PSM) -700% 8.00 [1.07-59.6] death 6/15 1/20 Basheer -13% 1.13 [1.05-1.21] death 45/140 29/250 Sisinni -7% 1.07 [0.89-1.29] death 93/253 251/731 Pérez-Segura -49% 1.49 [1.20-1.80] death 66/155 183/608 Tau​2​ = 0.17; I​2​ = 95.0% Prophylaxis 4% 0.96 [0.70-1.31] 2,074/15,059 3,654/20,520 4% improvement All studies 17% 0.83 [0.72-0.96] 3,610/31,838 5,405/38,437 17% improvement 21 aspirin COVID-19 serious outcomes c19aspirin.com Dec 3, 2021 Tau​2​ = 0.07; I​2​ = 90.8%; Z = 2.52 Effect extraction pre-specified Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY (RCT) 6% 0.94 [0.91-0.98] no disch. 7,351 (n) 7,541 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00; I​2​ = 0.0% Late treatment 6% 0.94 [0.91-0.98] 0/7,351 0/7,541 6% improvement All studies 6% 0.94 [0.90-0.98] 0/7,351 0/7,541 6% improvement 1 aspirin COVID-19 recovery result c19aspirin.com Dec 3, 2021 Tau​2​ = 0.00; I​2​ = 0.0%; Z = 2.74 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huh 71% 0.29 [0.14-0.58] population-based cohort Improvement, RR [CI] Treatment Control Merzon 28% 0.72 [0.53-0.99] 73/1,621 589/8,856 Kim (PSM) 33% 0.67 [0.30-1.36] 15/136 20/136 Tau​2​ = 0.13; I​2​ = 67.0% Prophylaxis 44% 0.56 [0.33-0.93] 88/1,757 609/8,992 44% improvement All studies 44% 0.56 [0.33-0.93] 88/1,757 609/8,992 44% improvement 3 aspirin COVID-19 case results c19aspirin.com Dec 3, 2021 Tau​2​ = 0.13; I​2​ = 67.0%; Z = 2.26 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Liu (PSM) -2% 1.02 [0.64-1.61] viral time 24 (n) 24 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00; I​2​ = 0.0% Late treatment -2% 1.02 [0.64-1.61] 0/24 0/24 -2% improvement Merzon 10% 0.90 [0.82-1.00] viral time 73 (n) 589 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00; I​2​ = 0.0% Prophylaxis 10% 0.90 [0.82-1.00] 0/73 0/589 10% improvement All studies 9% 0.91 [0.83-1.00] 0/97 0/613 9% improvement 2 aspirin COVID-19 viral clearance results c19aspirin.com Dec 3, 2021 Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.94 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Horby (RCT) 4% 0.96 [0.89-1.04] death 1,222/7,351 1,299/7,541 Improvement, RR [CI] Treatment Control RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) Tau​2​ = 0.00; I​2​ = 0.0% Late treatment 4% 0.96 [0.91-1.01] 1,222/14,702 1,299/15,082 4% improvement All studies 4% 0.96 [0.91-1.01] 1,222/14,702 1,299/15,082 4% improvement 2 aspirin COVID-19 Randomized Controlled Trials c19aspirin.com Dec 3, 2021 Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.47 Effect extraction pre-specified Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Horby (RCT) 4% 0.96 [0.89-1.04] 1,222/7,351 1,299/7,541 Improvement, RR [CI] Treatment Control RECOVERY (RCT) 4% 0.96 [0.89-1.04] 7,351 (n) 7,541 (n) Tau​2​ = 0.00; I​2​ = 0.0% Late treatment 4% 0.96 [0.91-1.01] 1,222/14,702 1,299/15,082 4% improvement All studies 4% 0.96 [0.91-1.01] 1,222/14,702 1,299/15,082 4% improvement 2 aspirin COVID-19 RCT mortality results c19aspirin.com Dec 3, 2021 Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.47 Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alamdari -28% 1.28 [0.67-2.43] death 9/53 54/406 Improvement, RR [CI] Treatment Control Meizlish (PSM) 48% 0.52 [0.34-0.81] death 319 (n) 319 (n) Liu (PSM) 75% 0.25 [0.07-0.87] death 2/28 11/204 Mura 15% 0.85 [0.69-1.01] death 527 (n) 527 (n) Chow 47% 0.53 [0.31-0.90] death 26/98 73/314 Sahai (PSM) 13% 0.87 [0.56-1.34] death 33/248 38/248 Abdelwahab -8% 1.08 [0.15-3.82] ventilation 11/31 6/36 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Zhao 43% 0.57 [0.41-0.78] death 121/473 140/473 RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) Tau​2​ = 0.06; I​2​ = 76.2% Late treatment 26% 0.74 [0.60-0.91] 216/9,252 345/10,203 26% improvement Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Improvement, RR [CI] Treatment Control Yuan 4% 0.96 [0.47-1.72] death 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] death 272/6,300 661/6,300 Merzon 28% 0.72 [0.53-0.99] cases 73/1,621 589/8,856 Mulhem -14% 1.14 [0.93-1.40] death 300/1,354 216/1,865 Chow (PSM) 19% 0.81 [0.76-0.87] death 1,280/6,781 2,271/10,566 Kim (PSM) -700% 8.00 [1.07-59.6] death 6/15 1/20 Basheer -13% 1.13 [1.05-1.21] death 45/140 29/250 Sisinni -7% 1.07 [0.89-1.29] death 93/253 251/731 Pérez-Segura -49% 1.49 [1.20-1.80] death 66/155 183/608 Tau​2​ = 0.16; I​2​ = 94.4% Prophylaxis 8% 0.92 [0.69-1.22] 2,147/16,680 4,243/29,376 8% improvement All studies 18% 0.82 [0.69-0.97] 2,363/25,932 4,588/39,579 18% improvement 20 aspirin COVID-19 peer reviewed trials c19aspirin.com Dec 3, 2021 Tau​2​ = 0.10; I​2​ = 90.6%; Z = 2.31 Effect extraction pre-specified Favors aspirin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alamdari -28% 1.28 [0.67-2.43] death 9/53 54/406 Improvement, RR [CI] Treatment Control Meizlish (PSM) 48% 0.52 [0.34-0.81] death 319 (n) 319 (n) Liu (PSM) 75% 0.25 [0.07-0.87] death 2/28 11/204 Liu (PSM) 81% 0.19 [0.05-0.78] death 1/28 9/204 Liu (PSM) -2% 1.02 [0.64-1.61] viral time 24 (n) 24 (n) Mura 15% 0.85 [0.69-1.01] death 527 (n) 527 (n) Mura 37% 0.63 [0.47-0.83] death 305 (n) 305 (n) Chow 47% 0.53 [0.31-0.90] death 26/98 73/314 Chow 44% 0.56 [0.37-0.85] ventilation 35/98 152/314 Chow 43% 0.57 [0.38-0.85] ICU 38/98 160/314 Sahai (PSM) 13% 0.87 [0.56-1.34] death 33/248 38/248 Horby (RCT) 4% 0.96 [0.89-1.04] death 1,222/7,351 1,299/7,541 Horby (RCT) 17% 0.83 [0.66-1.04] death 129/466 169/513 Horby (RCT) 7% 0.93 [0.82-1.05] death 1,222/7,351 1,299/7,541 Horby (RCT) 5% 0.95 [0.87-1.05] ventilation 772/6,993 829/7,169 Abdelwahab -8% 1.08 [0.15-3.82] ventilation 11/31 6/36 Al Harthi (PSM) 27% 0.73 [0.56-0.97] death 98/176 107/173 Al Harthi (PSM) 14% 0.86 [0.65-1.14] death 95/176 97/175 Kim (PSM) 34% 0.66 [0.36-1.23] death 14/124 23/135 Kim (PSM) -102% 2.02 [0.83-4.90] ventilation 13/124 7/135 Kim (PSM) -91% 1.91 [0.57-6.35] ICU 7/124 4/135 Zhao 43% 0.57 [0.41-0.78] death 121/473 140/473 Zhao 28% 0.72 [0.54-0.96] death 473 (n) 1,597 (n) RECOVERY (RCT) 4% 0.96 [0.89-1.04] death 7,351 (n) 7,541 (n) RECOVERY (RCT) 17% 0.83 [0.66-1.04] death 7,351 (n) 7,541 (n) RECOVERY (RCT) 5% 0.95 [0.87-1.05] ventilation 7,351 (n) 7,541 (n) RECOVERY (RCT) 6% 0.94 [0.91-0.98] no disch. 7,351 (n) 7,541 (n) RECOVERY (RCT) 16% 0.84 [0.71-0.99] no disch. 7,351 (n) 7,541 (n) Huh 71% 0.29 [0.14-0.58] cases population-based cohort Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Yuan 4% 0.96 [0.47-1.72] death 11/52 29/131 Osborne (PSM) 59% 0.41 [0.35-0.48] death 272/6,300 661/6,300 Osborne (PSM) 60% 0.40 [0.33-0.48] death 170/6,814 427/6,814 Merzon 28% 0.72 [0.53-0.99] cases 73/1,621 589/8,856 Merzon 62% 0.38 [0.02-4.94]